What are the recommendations for switching a patient from Advair Diskus (fluticasone propionate 250 µg/salmeterol 50 µg per inhalation, twice daily) to AirSupra (fluticasone furoate 100 µg/vilanterol 25 µg, once daily)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Do Not Switch from Advair Diskus to AirSupra

I cannot recommend switching from Advair Diskus 250/50 to AirSupra because AirSupra does not exist as a marketed product. You may be confusing product names or referring to a different medication.

Clarifying the Confusion

Based on available evidence, there is no FDA-approved inhaler called "AirSupra." If you're considering switching to a once-daily ICS/LABA combination, you likely mean one of these products:

  • Breo Ellipta (fluticasone furoate/vilanterol 100/25 or 200/25 mcg once daily)
  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol - triple therapy)

If You Mean Breo Ellipta (FF/VI)

Switching from Advair Diskus 250/50 twice daily to Breo Ellipta 100/25 once daily is reasonable and supported by evidence 1, 2.

Dosing Equivalence

  • Advair Diskus 250/50 mcg twice daily → Breo Ellipta 100/25 mcg once daily
  • Advair Diskus 500/50 mcg twice daily → Breo Ellipta 200/25 mcg once daily

The fluticasone furoate in Breo has enhanced glucocorticoid receptor affinity (18 times greater than dexamethasone) compared to fluticasone propionate, allowing for lower nominal doses 3.

Evidence for Switching

Non-inferiority has been demonstrated: In a 24-week RCT of 1,504 patients with well-controlled asthma, FF/VI 100/25 once daily was non-inferior to FP/SAL 250/50 twice daily for evening trough FEV1 (difference: 19 mL, 95% CI -11 to 49) 1. Both treatments improved lung function compared to fluticasone propionate alone, and FF/VI increased rescue-free and symptom-free 24-hour periods by 1.2% compared to FP/SAL 1.

Real-world effectiveness: A prospective switching study showed that patients with symptomatic asthma on FP/SM 250/50 twice daily who switched to FF/VI 100/25 once daily experienced improved FEV1 at 4 weeks (maintained through 12 weeks), improved ACT scores, and decreased FeNO from 8 weeks 4. Notably, 62% of patients with ACT <20 before switching achieved ACT >20 after switching 4.

Safety Considerations

The safety profile of FF/VI is similar to FP/SAL 1, 5. Common adverse events include:

  • Oral/oropharyngeal candidiasis (most common)
  • Dysphonia
  • Headache
  • Nasopharyngitis

Pneumonia risk: No significant difference in pneumonia hospitalization risk has been observed between fluticasone-based products and budesonide-based products in COPD populations 6, 7.

Practical Switching Protocol

  1. Direct switch: Stop Advair Diskus 250/50 twice daily and start Breo Ellipta 100/25 once daily the next day
  2. Timing: Administer Breo once daily at the same time each day (typically morning)
  3. Follow-up: Assess symptom control at 4 weeks using ACT score
  4. Monitoring: If control deteriorates, consider stepping up to Breo 200/25 once daily

When NOT to Switch

  • Patient has difficulty with once-daily adherence (prefers twice-daily reminder)
  • Patient is well-controlled and satisfied with current therapy
  • Cost considerations favor generic Advair Diskus
  • Patient has COPD rather than asthma (different guideline recommendations apply 8)

The key advantage of FF/VI is once-daily dosing, which may improve adherence 5. However, if the patient is already adherent to twice-daily Advair and well-controlled, there is no compelling clinical reason to switch.

References

Related Questions

Which inhaler is equivalent to Breo Ellipta (fluticasone furoate/vilanterol) and Advair (fluticasone propionate/salmeterol)?
What is a good alternative to Breo Ellipta (fluticasone furoate/vilanterol) 100 µg once daily?
How many times per day should fluticasone propionate plus vilanterol (Relvar Ellipta) be administered?
In a patient with asthma, can the dose of Breo (fluticasone furoate/vilanterol) 100 µg/25 µg be increased from one puff daily to two puffs daily when entering the yellow zone of the asthma action plan?
What is the purpose of Advair (fluticasone propionate + salmeterol) and the Ellipta dry‑powder inhaler in the maintenance treatment of adult asthma and COPD?
For an adult with asthma currently using Advair Diskus (fluticasone 250 µg/salmeterol 50 µg) 1 puff twice daily, is it appropriate to switch to or add Breztri (budesonide/formoterol/glycopyrrolate) and what are the recommendations?
I have hypokalemia with a serum potassium of about 3.0‑3.1 mEq/L and am awaiting knee debridement; should I wait to correct the low potassium before surgery?
What are the causes of a narrow‑complex tachycardia triggered by a fight‑or‑flight response, and which subsequent investigations and differential diagnoses should be pursued?
What is the recommended early treatment for vaginal candidiasis in pregnancy?
What does a reverse triiodothyronine (rT3) level indicate?
In a patient with negative laboratory tests but Lyme disease–like symptoms that have improved after doxycycline, what is the recommended management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.